Latest blog articles
-
With its judgment in case Stichting Rookpreventie Jeugd and Others (C-160/20) of 22 February 2022, the Grand Chamber of the Court of Justice of the European Union (Court of Justice) has set a fundamental milestone on the legal status and consequences of incorporating global standards in EU...
-
The completion and consolidation of the EU internal market has relied on the rule-making activities of private actors for more than three decades now. Following the regulatory technique of the New Approach, EU institutions have entrusted standard-setting organisations, composed of experts and...
-
How do we guarantee access to COVID-19 vaccines and therapies, and secure health-related human rights for all? We’ve heard a string of promises in the race for new vaccines and therapies.
-
It’s been almost a month since the COVID-19 pandemic has drastically changed the way we live and work. Now that we are more used to, in a manner of speaking, the extraordinary measures to curtail the rampant spread of the virus, it’s time to seriously consider, and openly discuss, this crisis’...
-
The European Environmental Agency (EEA) has recently published its latest ‘State of the Environment’ report (SOER 2020). Published every 5 years as part of the tasks of EEA’s mandate, the report contains a comprehensive assessment on the state of, trends in, and prospects for the protection of the...
-
It is always exciting to await a final decision of the Court of Justice of the European Union. The judgement in C-619/18, Art. 258 TFEU infringement case against Republic of Poland, is even more of a case in point, given its relevance for the European Union values and the mechanisms designed to hold...
-
The Polish turn away from democracy, named by Sadurski as anti-constitutional populist backsliding, has taken on a new dramatic and bold turn involving the active use of the available tools by the judges to question and address the rule of law problems in Poland. The judges seem to be fighting back...
-
Globally the majority of health-related R&D is invested in medicines with substantial guaranteed returns, yet what is missing is extensive R&D targeted at diseases overwhelmingly prevalent in developing countries. This threatens long-term availability of medicines and treatment options for these...